What is the Atlas of MS?
The Atlas of MS is the most comprehensive worldwide study of the epidemiology of MS and the global availability and accessibility of resources for people with MS.
STATISTICS CATEGORY:
FIND STATISTICS FOR:
| Country of Interest:
|
||||
| % of people who can afford each DMT in the country of Interest | World Bank category Upper middle income | WHO region Americas | Global results | |
|---|---|---|---|---|
| Estimated % of people with MS who can afford each DMT | ||||
| Alemtuzumab | 60% | 45% | 84% | 65% |
| Azathioprine | 90% | 87% | 85% | 84% |
| Cladribine (subcutaneous or IV) | N/A - This DMT not available in the country or unable to be prescribed for MS | 0% | 0% | 40% |
| Cladribine (oral) | 60% | 23% | 58% | 70% |
| Cyclophosphamide | 60% | 46% | 61% | 77% |
| Dimethyl fumarate | 70% | 82% | 82% | 90% |
| Diroximel fumarate | N/A - This DMT not available in the country or unable to be prescribed for MS | 0% | 0% | 46% |
| Fingolimod | 90% | 61% | 87% | 86% |
| Fludarabine | N/A - This DMT not available in the country or unable to be prescribed for MS | 0% | 0% | 14% |
| Glatiramer acetate | 80% | 90% | 84% | 83% |
| Interferon-beta 1a | 80% | 97% | 85% | 86% |
| Interferon-beta 1b | 80% | 95% | 84% | 85% |
| IV Immunoglobulin (IVIG) | 50% | 56% | 71% | 62% |
| Leflunomide | N/A - This DMT not available in the country or unable to be prescribed for MS | 6% | 48% | 14% |
| Methotrexate | 80% | 35% | 58% | 70% |
| Minocycline | N/A - This DMT not available in the country or unable to be prescribed for MS | 3% | 49% | 11% |
| Mitoxantrone | 60% | 45% | 61% | 73% |
| Monomethyl fumarate | N/A - This DMT not available in the country or unable to be prescribed for MS | 0% | 0% | 1% |
| Mycophenolate mofetil | 50% | 15% | 54% | 31% |
| Natalizumab | 80% | 58% | 85% | 77% |
| Ocrelizumab | 40% | 34% | 62% | 76% |
| Ofatumumab | 40% | 8% | 53% | 60% |
| Ozanimod | 50% | 6% | 5% | 45% |
| Peginterferon-beta 1a | 75% | 53% | 57% | 70% |
| Ponesimod | N/A - This DMT not available in the country or unable to be prescribed for MS | 0% | 0% | 42% |
| Rituximab | 70% | 43% | 62% | 81% |
| Siponimod | 60% | 11% | 53% | 57% |
| Teriflunomide | 80% | 84% | 84% | 88% |
Please note only 61 countries were able to provide estimates for this question and the data is highly variable within World Bank categories and WHO regions, with many outliers.
Explore the latest MS data
Access the latest Atlas of MS reports, infographics, slides and datasets to support research, advocacy and policy development. Planning an analysis or publication? Contact the Atlas team at [email protected] for guidance on methodology, data interpretation and related work.
Powerful tool for change
The information in the Atlas of MS can be a powerful advocacy tool, shining a spotlight on MS and raising awareness of the lack of adequate resources available to diagnose, inform, treat, rehabilitate and support people with MS worldwide.
With thanks to…
Worldwide collaboration
The Atlas of MS relies on data supplied by MS organisations from around the world. We are most grateful to the country coordinators and their colleagues for taking the time and effort to gather the information and data.
How others have been making a difference
The Atlas of MS is one of the strongest examples of what the global MS movement can achieve through collaboration. By bringing together evidence from countries around the world, it helps inform policy, strengthen advocacy and guide future investment in research and healthcare. The Atlas also highlights the need for continued investment in surveillance, registries and data systems to strengthen our understanding of the true burden of MS. Better data lead to better decisions and, ultimately, better outcomes for people affected by MS worldwide.
Professor Mario Alberto Battaglia
Chair, MS International Federation (MSIF) and President of the Italian MS Society (Associazione Italiana Sclerosi Multipla [AISM])